tradingkey.logo

CRISPR Therapeutics AG

CRSP

57.840USD

+1.580+2.81%
收盘 09/15, 16:00美东报价延迟15分钟
5.11B总市值
亏损市盈率 TTM

CRISPR Therapeutics AG

57.840

+1.580+2.81%
关于 CRISPR Therapeutics AG 公司
CRISPR Therapeutics AG 是一家总部位于瑞士的基因编辑公司,专注于开发基于 CRISPR/Cas9 的疗法。CRISPR/Cas9 代表成簇的规律间隔短回文重复序列 (CRISPR)/CRISPR 相关蛋白 9 (Cas9),是一种基因编辑技术,即精确改变基因组 DNA 特定序列的过程。该公司旨在应用这项技术来破坏、删除、纠正和插入基因,以治疗基因定义的疾病并设计先进的细胞疗法。该公司已获得涵盖 CRISPR/Cas9 和相关技术的知识产权 (IP) 的权利,并且还参与了自己的知识产权研究和其他许可工作。公司的产品开发和合作战略旨在充分利用 CRISPR/Cas9 平台的潜力,同时最大限度地提高成功开发其候选产品的可能性。
公司简介
公司代码CRSP
公司名称CRISPR Therapeutics AG
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
员工数量393
证券类型Ordinary Share
年结日Oct 19
公司地址Baarerstrasse 14
城市ZUG
上市交易所NASDAQ Global Market Consolidated
国家Switzerland
邮编6300
电话41415613279
网址https://crisprtx.com/
公司代码CRSP
上市日期Oct 19, 2016
CEODr. Samarth Kulkarni, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Sandesh Mahatme
Mr. Sandesh Mahatme
Independent Director
Independent Director
--
--
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
--
--
Dr. Maria Fardis, Ph.D.
Dr. Maria Fardis, Ph.D.
Independent Director
Independent Director
--
--
Dr. H. Edward Fleming, Jr., M.D.
Dr. H. Edward Fleming, Jr., M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
292.63K
+4.25%
Dr. Raju Prasad, Ph.D.
Dr. Raju Prasad, Ph.D.
Chief Financial Officer
Chief Financial Officer
13.01K
+30.05%
Mr. John Thomas Greene
Mr. John Thomas Greene
Independent Director
Independent Director
7.00K
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
270.00
--
Mr. James R. Kasinger, J.D.
Mr. James R. Kasinger, J.D.
General Counsel, Secretary
General Counsel, Secretary
--
--
Dr. Naimish Patel, M.D.
Dr. Naimish Patel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
其他
69.05%
持股股东
持股股东
占比
ARK Investment Management LLC
11.20%
Capital International Investors
6.15%
BlackRock Institutional Trust Company, N.A.
5.96%
T. Rowe Price Investment Management, Inc.
4.05%
State Street Global Advisors (US)
3.60%
其他
69.05%
股东类型
持股股东
占比
Investment Advisor
46.51%
Investment Advisor/Hedge Fund
21.68%
Hedge Fund
3.78%
Venture Capital
3.45%
Research Firm
3.18%
Individual Investor
1.64%
Bank and Trust
1.57%
Pension Fund
0.45%
Sovereign Wealth Fund
0.45%
其他
17.31%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
949
75.06M
82.87%
+271.52K
2025Q1
952
68.11M
78.87%
-5.61M
2024Q4
955
68.20M
79.52%
-1.17M
2024Q3
962
64.14M
75.29%
-1.47M
2024Q2
976
63.22M
74.44%
-1.89M
2024Q1
986
62.72M
74.09%
+4.47M
2023Q4
985
55.14M
69.41%
-4.96M
2023Q3
992
55.19M
69.50%
-6.68M
2023Q2
1037
54.86M
69.51%
-8.28M
2023Q1
1053
55.90M
70.89%
-6.49M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
ARK Investment Management LLC
10.17M
11.77%
+1.19M
+13.29%
Mar 31, 2025
Capital International Investors
6.07M
7.03%
-2.67M
-30.54%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.41M
2.8%
-100.08K
-3.98%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.80M
4.4%
-13.61K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
2.41M
2.79%
-80.26K
-3.22%
Mar 31, 2025
Two Sigma Investments, LP
1.99M
2.3%
+1.60M
+407.93%
Mar 31, 2025
Orbis Investment Management Ltd.
1.56M
1.81%
+86.81K
+5.88%
Mar 31, 2025
UBS Financial Services, Inc.
1.73M
2%
-94.39K
-5.18%
Mar 31, 2025
Amova Asset Management Co., Ltd.
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
Amova Asset Management Americas, Inc
2.54M
2.94%
-205.79K
-7.49%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
ARK Genomic Revolution ETF
9.19%
Global X Genomics & Biotechnology ETF
5.61%
ARK Innovation ETF
4.11%
AXS Green Alpha ETF
3.95%
WisdomTree BioRevolution Fund
3.07%
SPDR S&P Biotech ETF
1.51%
Amplify Small-Mid Cap Equity ETF
1.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.86%
iShares Exponential Technologies ETF
0.52%
iShares Biotechnology ETF
0.41%
查看更多
ARK Genomic Revolution ETF
占比9.19%
Global X Genomics & Biotechnology ETF
占比5.61%
ARK Innovation ETF
占比4.11%
AXS Green Alpha ETF
占比3.95%
WisdomTree BioRevolution Fund
占比3.07%
SPDR S&P Biotech ETF
占比1.51%
Amplify Small-Mid Cap Equity ETF
占比1.07%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.86%
iShares Exponential Technologies ETF
占比0.52%
iShares Biotechnology ETF
占比0.41%
分红派息
近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
KeyAI